Colchicine in Acute Myocardial Infarction

Area of Science:

• Cardiology
• Pharmacology
• Inflammation Research

Background:

• Inflammation plays a role in adverse cardiovascular events.
• Previous trials suggested colchicine might reduce cardiovascular risks.

Purpose of the Study:

• To evaluate the efficacy of colchicine in reducing cardiovascular events in patients post-myocardial infarction.
• To assess the impact of colchicine on C-reactive protein levels and safety outcomes.

Main Methods:

• A multicenter, 2x2 factorial randomized trial involving 7062 patients post-myocardial infarction.
• Patients received either colchicine or placebo, and spironolactone or placebo.
• The primary outcome was a composite of cardiovascular death, recurrent myocardial infarction, stroke, or ischemia-driven revascularization over a median 3-year follow-up.

Main Results:

• No significant difference in the primary composite outcome was observed between the colchicine and placebo groups (9.1% vs. 9.3%, HR 0.99, P=0.93).
• Colchicine significantly reduced C-reactive protein levels at 3 months (-1.28 mg/L).
• Diarrhea was more frequent in the colchicine group (10.2% vs. 6.6%), but serious infection rates were similar.

Conclusions:

• Early colchicine treatment for 3 years post-myocardial infarction did not reduce the composite incidence of major cardiovascular events.
• Colchicine demonstrated anti-inflammatory effects by lowering C-reactive protein but was associated with increased gastrointestinal side effects.